Clinical use of gadobutrol for contrast-enhanced magnetic resonance imaging of neurological diseases

Reports in Medical Imaging

Volumn 5, Issue 1, 2012, Pages 15-22

  Cheng, Kenneth T ^a   Cheng, Hannah Y ^b   Leung, Kam ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Freelance Technical Writer   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CE MRI; CNS imaging; Gadolinium; Gadovist; Gd BT DO3A; MRI contrast agent

Indexed keywords

GADOBUTROL; GADOLINIUM; PLACEBO;

BLOOD BRAIN BARRIER; BRAIN CANCER; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; REVIEW; SMELLING DISORDER; TASTE DISORDER;

EID: 84863426938     PISSN: None     EISSN: 11791586     Source Type: Journal    
DOI: 10.2147/RMI.S20665     Document Type: Review

References (53)

1. Burtea C, Laurent S, Vander Elst L, Muller RN. Contrast agents: magnetic resonance. Handb Exp Pharmacol. 2008;(185 Pt 1):135-165.
2. Strijkers GJ, Mulder WJ, van Tilborg GA, Nicolay K. MRI contrast agents: current status and future perspectives. Anticancer Agents Med Chem. 2007;7(3):291-305.
3. Giesel FL, Mehndiratta A, Essig M. High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur Radiol. 2010; 20(10):2461-2474.
4. Roberts TP, Chuang N, Roberts HC. Neuroimaging: do we really need new contrast agents for MRI? Eur J Radiol. 2000;34(3):166-178.
5. Rinck PA, Myhr G. Gadolinium chelates: clinical applications. In: Dawson P, Cosgrove DO, Grainger RG, editors. Textbook of Contrast Media. Oxford, UK: Isis Medical Media Ltd; 1999:333-353.
6. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008;66(2):160-167.
7. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol. 2008;66(2):175-179.
8. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging. 2007;25(5):884-899.
9. Kuo PH. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol. 2008;5(1): 29-35.
10. Niendorf HP, Alhassan A, Geens VR, Clauss W. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol. 1994;29(Suppl 2): S179-S182.
11. Duyn JH, Koretsky AP. Novel frontiers in ultra-structural and molecular MRI of the brain. Curr Opin Neurol. 2011;24(4):386-393.
12. Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging. 2011;29(5):587-600.
13. Bogdanov A Jr, Mazzanti ML. Molecular magnetic resonance contrast agents for the detection of cancer: past and present. Semin Oncol. 2011;38(1):42-54.
14. Gallagher FA. An introduction to functional and molecular imaging with MRI. Clin Radiol. 2010;65(7):557-566.
15. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol. 1999;9(5):998-1004.
16. Rebeles F, Fink J, Anzai Y, Maravilla KR. Blood-brain barrier imaging and therapeutic potentials. Top Magn Reson Imaging. 2006;17(2):107-116.
17. Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol. 2010;183(1):27-33.
18. Idee JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009;30(6):1249-1258.
19. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1(3):128-137.
20. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging. 2009;30(6):1240-1248.
21. Platzek J, Blaszkiewicz P, Gries H, et al. Synthesis and structure of a new macrocyclic polyhydroxylated gadolinium chelate used as a contrast agent for magnetic resonance imaging. Inorg Chem. 1997; 36(26):6086-6093.
22. Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol. 2001;36(2):115-122.
23. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21(4):469-490.
24. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial. 2007;20(3):179-185.
25. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 2007;72(3):260-264.
26. Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging. 2007;25(5):881-883.
27. Cheng KT. Gadobutrol. Gd-DO3A-butrol. In: Molecular Imaging and Contrast Agent Database (MICAD) [database on the Internet]. Bethesda (MD): National Library of Medicine (US), NCBI; 2004-2012. Available from: http://www.ncbi.nlm.nih.gov/books/NBK23589/. Accessed February 9, 2012.
28. Gadovist® [product information]. 2010. Available from: http:// www.medsafe.govt.nz/profs/datasheet/g/Gadovistinj.pdf. Accessed February 9, 2012.
29. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol. 1995;21(1):1-10.
30. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (magnevist), gadobutrol (gadovist), and gadobenate dimeglumine (multihance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41(3):213-221.
31. Fink C, Bock M, Kiessling F, Delorme S. Interstitial magnetic resonance lymphography with gadobutrol in rats: evaluation of contrast kinetics. Invest Radiol. 2002;37(12):655-662.
32. Frigeni V, Miragoli L, Grotti And A, Lorusso V. Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: evaluation of somatosensory evoked potentials. Invest Radiol. 2001;36(10):561-572.
33. Kawai J, Takahashi M, Kato N, Takashima K, Miyazawa T. Comparison of a 1.0 molar and a 0.5 molar formulation of gadobutrol in dynamic MR imaging of the liver in rats with hepatocellular carcinoma. Magn Reson Imaging. 1999;17(1):91-97.
34. Le Duc G, Corde S, Charvet A, et al. In vivo measurement of gadolinium concentration in a rat glioma model by monochromatic quantitative computed tomography: comparison between gadopentetate dimeglumine and gadobutrol. Invest Radiol. 2004;39(7):385-393.
35. Reimer P, Allkemper T, Bremer C, et al. Assessment of reperfusion injury by means of MR contrast agents in rat liver. J Magn Reson Imaging. 1997;7(3):490-494.
36. Attenberger UI, Runge VM, Jackson CB, et al. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol. 2009;44(5):251-256.
37. Attenberger UI, Runge VM, Morelli JN, Williams J, Jackson CB, Michaely HJ. Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T. J Magn Reson Imaging. 2010;31(3):549-555.
38. Kramer H, Runge VM, Naul LG, Loynachan AT, Reiser MF, Wintersperger BJ. Brain MRI with single-dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg Gadoterate meglumine. AJR Am J Roentgenol. 2010;194(5):1337-1342.
39. Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann H, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994;29(7):709-715.
40. Essig M, Lodemann KP, Le-Huu M, Bruning R, Kirchin M, Reith W. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol. 2006;41(3):256-263.
41. Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol. 2002; 12(6):1550-1556.
42. Huppertz A, Rohrer M. Gadobutrol, a highly concentrated MR-imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radiol. 2004;14(Suppl 5):M12-M18.
43. Tombach B, Bremer C, Reimer P, et al. Pharmacokinetics of 1Mgadobutrol in patients with chronic renal failure. Invest Radiol. 2000;35(1):35-40.
44. Hahn G, Sorge I, Gruhn B, et al. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol. 2009;44(12):776-783.
45. Anzalone N, Gerevini S, Scotti R, Vezzulli P, Picozzi P. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol. 2009;50(8):933-940.
46. Kim ES, Chang JH, Choi HS, Kim J, Lee SK. Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine. AJNR Am J Neuroradiol. 2010;31(6):1055-1058.
47. Katakami N, Inaba Y, Sugata S, et al. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. Invest Radiol. 2011;46(7):411-418.
48. Anzalone N, Scarabino T, Venturi C, et al. Cerebral neoplastic enhancing lesions: Multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmolGd/kg body weight in a clinical setting. Eur J Radiol. 2011. Epub Sep 2.
49. Goyen M, Herborn CU, Vogt FM, et al. Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging. 2003;17(5):565-571.
50. Tombach B, Bremer C, Reimer P, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol. 2002; 178(1):105-109.
51. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging. 2007;26(5):1190-1197.
52. Voth M, Rosenberg M, Breuer J. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. Invest Radiol. 2011;46(11):663-671.
53. Briefing document for gadobutrol injection NDA 201,277, Bayer Health-Care Pharmaceuticals. January 21, 2011. Available from: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/ UCM240357.pdf. Accessed February 28, 2012.